Validea Detailed Fundamental Analysis

Validea's guru fundamental report shows Elevance Health (ELV) scored 75% using Pim van Vliet's Multi-Factor Investor model, which prioritizes low volatility, strong momentum, and high net payout yields. Despite passing market cap and standard deviation criteria, ELV's neutral momentum and net payout yield, culminating in a 'FAIL' on its final rank, positioned it below the 80% threshold typically signaling interest for this strategy.

Analysis

Elevance Health (ELV) was evaluated using Validea's quantitative model based on Pim van Vliet's Multi-Factor Investor strategy, achieving a score of 75%. This score is below the 80% threshold that typically indicates strategic interest. The model, which seeks to identify low-volatility stocks with strong momentum and high net payout yields, found ELV to be a mixed candidate. The company successfully passed the criteria for market capitalization and standard deviation, confirming its low-volatility characteristics. However, ELV registered only 'NEUTRAL' ratings for its 'Twelve Minus One Momentum' and 'Net Payout Yield'. Consequently, despite its stability, the stock received a 'FAIL' on its final rank within this specific factor-based framework, indicating it does not currently exhibit the combined attributes the strategy targets.

Key Decisions for Investors

• Investors following factor-based strategies similar to Pim van Vliet's should note that ELV currently fails to qualify due to its neutral signals on momentum and net payout yield.
• While the stock's low-volatility profile is confirmed, its performance may lag for investors who prioritize momentum or shareholder returns as primary drivers.
• Consider monitoring ELV for a significant improvement in its net payout yield or a positive shift in price momentum, as these would be the key catalysts required for it to become attractive under this multi-factor lens.